Beyond First-Line: Therapy Targets Explored in Biliary Tract Cancer

In an interview with Targeted Oncology, Linda Y. Wu, MD, assistant professor of Medicine at Columbia University Irving Medical Center, provides an overview of therapeutic strategies emerging for biliary tract cancers, a rare and challenging group of malignancies with limited treatment options.

Biliary tract cancers are less common than pancreatic cancer, creating additional barriers to drug development and clinical trial enrollment. Current standard-of-care treatment in the first-line setting typically includes chemotherapy combined with immunotherapy, although the precise contribution of immunotherapy to overall outcomes remains an area of ongoing investigation.

A major area of progress in biliary tract cancers lies in molecularly targeted therapies. Approximately 30% of patients harbor actionable genomic alterations, opening the door to more personalized treatment approaches. Among the most well-established targets are IDH1 mutations and FGFR2 fusions, for which second-generation inhibitors are currently being developed to improve efficacy and overcome resistance. In addition, HER2-directed therapies have shown activity in select patient subsets, while other targets such as BRAF mutations are also being explored.

More recently, KRAS mutations—present in a significant proportion of biliary tract cancers—have emerged as a potential therapeutic target. However, unlike pancreatic cancer, where KRAS alterations are more uniform, biliary cancers exhibit greater molecular heterogeneity. This diversity makes it less likely that a single targeted therapy will benefit a broad patient population, reinforcing the need for biomarker-driven treatment strategies.

Looking ahead, efforts are increasingly focused on improving outcomes beyond the first-line setting. As many patients experience disease progression after initial therapy, there is a critical need to develop more effective second-line and subsequent treatment options. Ongoing research aims to refine targeted approaches and identify optimal sequencing strategies to extend survival and improve patient outcomes.